Should I adjust my methimazole (20 mg daily) dose given a free T3 (FT3) of 6.08 pmol/L, thyroglobulin (Tg) of 3.27 ng/mL, anti‑thyroglobulin antibodies (anti‑Tg) of 483.35 IU/mL, and anti‑thyroid peroxidase antibodies (anti‑TPO) of 126.74 IU/mL?

Critical Assessment: Your Methimazole Dose Requires Adjustment

You need to reduce your methimazole dose immediately. Your FT3 of 6.08 pmol/L indicates you are still hyperthyroid (assuming a typical reference range of approximately 3.1-6.8 pmol/L, though this is at the upper limit), and your significantly elevated thyroid antibodies (anti-Tg 483.35 IU/mL and anti-TPO 126.74 IU/mL) confirm active autoimmune thyroid disease, most likely Graves' disease.

Why Dose Adjustment is Needed

Your current 20 mg daily methimazole dose appears insufficient to achieve euthyroid status. The goal of antithyroid drug therapy is to normalize thyroid hormone levels (FT4 and FT3) while maintaining TSH in the normal range 1. When thyroid hormone levels normalize, methimazole doses should be reduced by 50% or more to maintain a euthyroid state 1.

However, your FT3 remains elevated, suggesting:

• Either you need a higher initial dose to bring thyroid hormones into normal range, OR
• You are in the initial treatment phase and need continued monitoring at the current dose

Critical Missing Information

You must check TSH and FT4 levels immediately to complete the clinical picture 1. The FT3 alone is insufficient for dose adjustment decisions. In Graves' disease:

• FT3 should be assayed when FT4 is normal but symptoms persist 2
• TSH may remain suppressed for weeks after FT4/FT3 normalize and is not initially useful for monitoring 2, 3
• During the euthyroid recovery phase, monitor primarily FT4 ± FT3 at least monthly until euthyroid status is achieved 2

Recommended Management Algorithm

If This is Early Treatment (First 3-4 Weeks):

1. Continue current dose and recheck FT4, FT3, and TSH in 3-4 weeks 2
2. If FT3 remains elevated with elevated FT4, increase methimazole to 30 mg daily 1
3. Monitor monthly until both FT4 and FT3 normalize

If You've Been on Treatment >4 Weeks:

1. Your dose is inadequate - increase to 30 mg daily 1
2. Recheck thyroid function in 3-4 weeks
3. Once FT4 and FT3 normalize, reduce dose by 50% (to 10-15 mg daily) 1

Once Euthyroid is Achieved:

• Maintenance dose typically 5-10 mg daily 1
• Monitor TSH and FT4 every 2-3 months 2
• Continue treatment for 12-18 months total before considering discontinuation 2

Significance of Your Antibody Levels

Your markedly elevated anti-thyroid antibodies have important implications:

Anti-TPO (126.74 IU/mL) and Anti-Tg (483.35 IU/mL):

• Confirm autoimmune thyroid disease 4, 5
• These antibodies often decrease during successful methimazole treatment 4
• Rising antibodies after treatment cessation predict relapse 4
• Should be rechecked at end of 12-18 month treatment course to assess remission risk 2, 6

Prognostic Value:

• Patients with persistently high antibodies have lower remission rates 4, 7
• A fall in antibody titers during treatment correlates with better outcomes 4, 7
• However, antibody changes during treatment have limited value for predicting individual outcomes 4

Critical Safety Monitoring

Given your current treatment, you must be aware of serious adverse effects 3:

Stop methimazole immediately and contact your physician if you develop:

• Fever or sore throat (agranulocytosis risk)
• Jaundice, dark urine, or light-colored stools (hepatotoxicity)
• New rash, especially with joint pain (vasculitis)
• Severe abdominal pain or persistent nausea

Baseline monitoring should include 1, 3:

• Complete blood count with differential
• Liver function tests (ALT, AST, bilirubin, alkaline phosphatase)
• These should be repeated if symptoms develop

Common Pitfalls to Avoid

1. Don't rely on TSH alone early in treatment - it remains suppressed for weeks after thyroid hormones normalize 2

2. Don't use "block-and-replace" therapy (high-dose methimazole + levothyroxine) - this increases adverse events without improving outcomes 1

3. Don't stop treatment prematurely - minimum 12-18 months needed for optimal remission rates 2

4. Don't ignore persistently elevated FT3 with normal FT4 - this indicates inadequate treatment and requires dose adjustment 2

Next Steps

1. Immediately check TSH and FT4 to complete your thyroid function assessment
2. Based on how long you've been on treatment, adjust dose as outlined above
3. Recheck thyroid function in 3-4 weeks
4. Plan for antibody measurement at end of treatment course to assess relapse risk
5. Ensure you have had baseline blood counts and liver function tests

Your elevated antibodies and borderline-high FT3 indicate active disease requiring continued vigilant management and likely dose optimization.